# Remternetug

Source: https://onco.cc/drugs/da-remternetug/  
OnCo record `da-remternetug` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Remternetug is an investigational amyloid antibody. It is not approved. Trial eligibility is not a treatment recommendation.

## Summary

Listed so the pipeline layer of the Alzheimer’s page has a concrete next antibody. Risks should not be copied from lecanemab or donanemab by assumption.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Code: LY3372993
- Modality: mAb
- Mechanism: Investigational amyloid-directed antibody.

## Sources

- ClinicalTrials.gov search: https://clinicaltrials.gov/search?intr=remternetug

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- targets: [Amyloid-beta](https://onco.cc/targets/da-target-amyloid-beta/)
- companies: [Eli Lilly](https://onco.cc/companies/da-lilly/)
- roadmaps: [Anti-amyloid medicines](https://onco.cc/roadmaps/da-roadmap-anti-amyloid/)

---
JSON: https://onco.cc/api/v1/entities/da-remternetug.json